empagliflozin

Known as: (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol, 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Early Glycaemic Control in Metformin Users Receiving Their First Add-On Therapy: A Population-Based Study of 4,734 People with… (More)
Is this relevant?
Highly Cited
2016
Highly Cited
2016
BACKGROUND Diabetes confers an increased risk of adverse cardiovascular and renal events. In the EMPA-REG OUTCOME trial… (More)
  • table 1
  • figure 1
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2016
Highly Cited
2016
AIMS We previously reported that in the EMPA-REG OUTCOME(®) trial, empagliflozin added to standard of care reduced the risk of 3… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
OBJECTIVE To investigate the efficacy, safety, and tolerability of empagliflozin in patients with type 2 diabetes and… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Diabetes is a leading cause of chronic kidney disease (CKD) worldwide. Optimum glycaemic control in patients with type… (More)
  • figure 1
  • table 1
  • table 2
  • figure 3
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Metformin is the recommended first-line pharmacotherapy for patients with type 2 diabetes. There is no consensus on… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
AIMS This study investigated the efficacy and tolerability of empagliflozin as add-on to pioglitazone ± metformin in patients… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
OBJECTIVE To investigate the efficacy and tolerability of empagliflozin as add-on to metformin and sulfonylurea in patients with… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
OBJECTIVE To investigate the long-term safety and efficacy of empagliflozin, a sodium glucose cotransporter 2 inhibitor… (More)
  • figure 1
  • table 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
AIMS Empagliflozin is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor in clinical development for the treatment of… (More)
Is this relevant?